Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Accuray Incorporated stock logo
ARAY
Accuray
$2.18
-0.9%
$2.51
$2.10
$4.30
$216.19M1.44448,838 shs359,241 shs
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$24.04
$24.02
$8.42
$24.25
$1.76B3.022.70 million shsN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$66.29
-1.3%
$69.78
$66.01
$100.59
$237.92M0.1226,545 shs24,010 shs
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$1.26
-0.8%
$1.26
$0.75
$7.44
$7.81M-1.119,238 shs1,127 shs
The Westaim Co. stock logo
WEDXF
Westaim
$2.72
-0.4%
$2.67
$2.13
$2.99
$350.33M0.4629,012 shs3,650 shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Accuray Incorporated stock logo
ARAY
Accuray
-0.90%+0.46%-11.29%-21.15%-20.58%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.00%0.00%0.00%0.00%0.00%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
-0.59%-0.68%-3.16%-18.56%-28.58%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
0.00%-6.91%-4.27%+39.04%-67.70%
The Westaim Co. stock logo
WEDXF
Westaim
-1.45%+1.12%-1.09%-0.05%+23.74%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Accuray Incorporated stock logo
ARAY
Accuray
3.6638 of 5 stars
3.50.00.04.62.61.70.6
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
2.3978 of 5 stars
0.03.01.74.22.01.71.3
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Accuray Incorporated stock logo
ARAY
Accuray
3.00
Buy$8.25278.44% Upside
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/AN/AN/AN/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
N/AN/AN/AN/A

Current Analyst Ratings

Latest GNMK, VAPO, UTMD, ARAY, and WEDXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/13/2024
Accuray Incorporated stock logo
ARAY
Accuray
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Accuray Incorporated stock logo
ARAY
Accuray
$447.61M0.48N/AN/A$0.56 per share3.89
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
$88.02M19.96N/AN/A$0.21 per share114.48
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$50.22M4.74$6.22 per share10.66$35.35 per share1.88
Vapotherm, Inc. stock logo
VAPO
Vapotherm
$67.60M0.12N/AN/A($9.01) per share-0.14
The Westaim Co. stock logo
WEDXF
Westaim
$8.63M40.59$1.39 per share1.96$3.95 per share0.69

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Accuray Incorporated stock logo
ARAY
Accuray
-$9.28M-$0.15N/A15.57N/A-3.25%-28.11%-3.05%5/1/2024 (Confirmed)
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
-$47.35M-$0.82N/AN/AN/A-16.95%-39.36%-13.02%N/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$16.64M$4.5714.51N/A33.12%13.53%12.68%N/A
Vapotherm, Inc. stock logo
VAPO
Vapotherm
-$58.19M-$9.90N/AN/A-84.74%N/A-65.84%5/1/2024 (Estimated)
The Westaim Co. stock logo
WEDXF
Westaim
$183.98M$1.302.09N/A2,132.63%37.84%34.98%5/14/2024 (Estimated)

Latest GNMK, VAPO, UTMD, ARAY, and WEDXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Accuray Incorporated stock logo
ARAY
Accuray
-$0.0050N/A+$0.0050N/AN/AN/A  
3/27/2024Q4 2023
The Westaim Co. stock logo
WEDXF
Westaim
N/A$0.26+$0.26$0.26N/A$1.67 million
2/22/2024Q4 2023
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A-$1.60-$1.60-$1.60N/A$19.73 million
1/31/202412/31/2023
Accuray Incorporated stock logo
ARAY
Accuray
-$0.05-$0.10-$0.05-$0.10$107.11 million$107.24 million    
1/30/2024Q4 2023
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A$1.18+$1.18$1.18N/A$12.33 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Accuray Incorporated stock logo
ARAY
Accuray
N/AN/AN/AN/AN/A
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
N/AN/AN/AN/AN/A
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
$1.201.81%+1.75%26.26%2 Years
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/AN/AN/AN/AN/A
The Westaim Co. stock logo
WEDXF
Westaim
$0.093.31%N/A6.92%N/A

Latest GNMK, VAPO, UTMD, ARAY, and WEDXF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/6/2024
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
quarterly$0.301.6%3/14/20243/15/20244/3/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Accuray Incorporated stock logo
ARAY
Accuray
3.53
1.58
0.84
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
0.75
4.33
3.84
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
N/A
22.56
20.53
Vapotherm, Inc. stock logo
VAPO
Vapotherm
N/A
2.43
1.23
The Westaim Co. stock logo
WEDXF
Westaim
N/A
4.23
4.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Accuray Incorporated stock logo
ARAY
Accuray
64.08%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
96.94%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
69.60%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
43.08%
The Westaim Co. stock logo
WEDXF
Westaim
N/A

Insider Ownership

CompanyInsider Ownership
Accuray Incorporated stock logo
ARAY
Accuray
3.78%
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
3.25%
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
6.50%
Vapotherm, Inc. stock logo
VAPO
Vapotherm
15.80%
The Westaim Co. stock logo
WEDXF
Westaim
4.21%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Accuray Incorporated stock logo
ARAY
Accuray
1,02499.17 million95.42 millionOptionable
GenMark Diagnostics, Inc. stock logo
GNMK
GenMark Diagnostics
61873.09 millionN/AOptionable
Utah Medical Products, Inc. stock logo
UTMD
Utah Medical Products
1693.59 million3.36 millionNot Optionable
Vapotherm, Inc. stock logo
VAPO
Vapotherm
1826.21 million5.23 millionNo Data
The Westaim Co. stock logo
WEDXF
Westaim
7128.80 million123.54 millionNot Optionable

GNMK, VAPO, UTMD, ARAY, and WEDXF Headlines

SourceHeadline
The Westaim Corporation Reports Q4 and Full Year 2023 ResultsThe Westaim Corporation Reports Q4 and Full Year 2023 Results
businesswire.com - March 27 at 4:25 PM
The Westaim Corporation Recognized on the TSX Venture 50 ListThe Westaim Corporation Recognized on the TSX Venture 50 List
businesswire.com - February 21 at 8:28 AM
Westaim Corp.Westaim Corp.
wsj.com - February 17 at 2:53 PM
DCK ELEVATES BILL BROWN TO PRESIDENTDCK ELEVATES BILL BROWN TO PRESIDENT
finance.yahoo.com - January 17 at 12:21 PM
Westaim (WEDXF) Price Target Increased by 6.07% to 3.93Westaim (WEDXF) Price Target Increased by 6.07% to 3.93
msn.com - November 27 at 5:22 PM
The Westaim GAAP EPS of $0.16The Westaim GAAP EPS of $0.16
seekingalpha.com - November 15 at 12:57 PM
The Westaim Corporation Reports Q3 2023 ResultsThe Westaim Corporation Reports Q3 2023 Results
finance.yahoo.com - November 14 at 4:56 PM
The Westaim GAAP EPS of $0.22, revenue of $35.9MThe Westaim GAAP EPS of $0.22, revenue of $35.9M
seekingalpha.com - August 15 at 9:22 PM
Westaim (WEDXF) Price Target Increased by 15.87% to 3.88Westaim (WEDXF) Price Target Increased by 15.87% to 3.88
msn.com - August 1 at 6:00 PM
Closing Bell: The Westaim Corp flat on Friday (WED)Closing Bell: The Westaim Corp flat on Friday (WED)
theglobeandmail.com - June 24 at 2:58 AM
Westaim Announces Pricing of Secondary Offering of Skyward Specialtys Common StockWestaim Announces Pricing of Secondary Offering of Skyward Specialty's Common Stock
technews.tmcnet.com - June 8 at 1:16 AM
Skyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shrSkyward Announces Pricing Of Secondary Offering Of 3.85 Mln Of Its Stock By Westaim At $23/shr
markets.businessinsider.com - June 8 at 1:16 AM
Westaim Announces Director ResignationWestaim Announces Director Resignation
technews.tmcnet.com - April 25 at 8:25 AM
Closing Bell: The Westaim Corp flat on Monday (WED)Closing Bell: The Westaim Corp flat on Monday (WED)
theglobeandmail.com - April 17 at 8:08 PM
The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50The Westaim Corporation Recognized as Top Sector Performer with TSX Venture 50
technews.tmcnet.com - February 21 at 9:55 AM
Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)Westaim Third Quarter 2022 Earnings: US$0.12 loss per share (vs US$0.011 profit in 3Q 2021)
nz.finance.yahoo.com - November 13 at 4:45 PM
WEDXF The Westaim CorporationWEDXF The Westaim Corporation
seekingalpha.com - October 1 at 5:43 PM
Is Westaim Corp (WEDXF) Stock a Good Investment?Is Westaim Corp (WEDXF) Stock a Good Investment?
aaii.com - September 6 at 10:24 AM
WEDXF.PK - Westaim Corp | Stock Price & Latest News | ReutersWEDXF.PK - Westaim Corp | Stock Price & Latest News | Reuters
reuters.com - September 3 at 9:42 PM
The Westaim Corporation Reports Q2 2022 ResultsThe Westaim Corporation Reports Q2 2022 Results
apnews.com - August 11 at 3:35 PM
The Westaim Corporation Reports Q1 2022 ResultsThe Westaim Corporation Reports Q1 2022 Results
finance.yahoo.com - May 17 at 11:18 AM
The Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor DayThe Westaim Corporation Announces Dates for Q1 2022 Results, AGM, and Investor Day
finance.yahoo.com - May 3 at 6:13 PM
Westaim earnings preview: what Wall Street is expectingWestaim earnings preview: what Wall Street is expecting
markets.businessinsider.com - April 14 at 10:42 AM
Heres what Wall Street expects from Westaims earnings reportHere's what Wall Street expects from Westaim's earnings report
markets.businessinsider.com - April 6 at 12:30 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Accuray logo

Accuray

NASDAQ:ARAY
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.
GenMark Diagnostics logo

GenMark Diagnostics

NASDAQ:GNMK
GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative panel, Blood Culture Identification Fungal Pathogen panel, and ePlex Gastrointestinal Pathogen Panel. In addition, it provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. Further, the company offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, thrombophilia risk test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test and eSensor SARS-CoV-2 Test. GenMark Diagnostics, Inc. sells its products through direct sales and technically specialized service organization in the United States, Europe, and internationally. The company was incorporated in 2010 and is headquartered in Carlsbad, California.
Utah Medical Products logo

Utah Medical Products

NASDAQ:UTMD
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Vapotherm logo

Vapotherm

NYSE:VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers High Velocity Therapy systems, such as HVT 2.0, Precision Flow Hi-VNI, Precision Flow Plus, and Precision Flow Classic which delivers non-invasive ventilatory support to patients by providing heated, humidified, and oxygenated air at a high velocity to treat patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor that provides compressed air necessary to run the precision flow systems in areas of the hospital without access to a wall gas source; aerosol aeroneb adaptor to facilitate delivery of aerosolized solutions; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol solutions for patients; and tracheostomy adaptors that simplifies the connection of the High Velocity Therapy systems to a tracheostomy collar used to wean patients off mechanical ventilation. In addition, the company offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Module, which helps clinicians maintain oxygen levels within a target range. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Westaim logo

Westaim

OTCMKTS:WEDXF
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.